In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AI And Big Data In Focus: What Is Preventing Faster Adoption In Health Care Settings?

Executive Summary

To the wider public and even governments, big data, predictive analytics and machine learning might appear to be recent phenomena that suddenly hold the answers to most of the health care delivery problems. But those who have been generating the debate and charting future adoption over the past several years know it is not as simple as that.

You may also be interested in...



Sanofi/Google Alliance To Apply Big Data To R&D, Commercial And Marketing Operations

Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.

Life After FDA: Rachel Sherman To Tackle Real World Evidence, Clinical Trial Efficiency

Sherman, who left the No. 2 post at FDA in January, is working part-time at Duke-Margolis and serving as a consultant to Medidata Solutions.

When Will POC Really Be On The Cusp Of Major Uptake?

Point-of-care/near-patient testing has been “two years away from major breakthrough” for at least two decades, but fast access to data via automation and IT means that progress might change at last. How the tests are paid for remains an issue. The future of POC was the theme of an investor discussion at the first DxPx conference, held during the Medica 2019 event in Germany.

Topics

UsernamePublicRestriction

Register

IV124237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel